Evidence map›Paper›PMID 25192935›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2014

Progressive increase in mtDNA 3243A>G heteroplasmy causes abrupt transcriptional reprogramming.

Martin Picard, Jiangwen Zhang, Saege Hancock, Olga Derbeneva, Ryan Golhar, Pawel Golik, Sean O'Hearn, Shawn Levy, Prasanth Potluri, Maria Lvova and 8 more

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 193 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
193citing papers in PubMed, 4 pooled it
10.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

193 citing papers in PubMed, 4 syntheses or guidelines pooled it, 297 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Beta-adrenergic blockade blunts inflammatory and antiviral/antibody gene expression responses to acute psychosocial stress.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2021
    Trial
  6. Trial
  7. Trial
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article

133 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 9 institutions in 6 countries.

Martin PicardCenter for Mitochondrial and Epigenomic Medicine, Children's Hospital of Philadelphia and the Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104;
Jiangwen ZhangSchool of Biological Sciences, The University of Hong Kong, Hong Kong, People's Republic of China;
Saege HancockTrovagene, San Diego, CA 92130;
Olga DerbenevaCenter for Mitochondrial and Epigenomic Medicine, Children's Hospital of Philadelphia and the Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104;
Ryan GolharCenter for Applied Genomics, Division of Genetics, Department of Pediatrics, and.
Pawel GolikInstitute of Genetics and Biotechnology, Warsaw University, 00-927, Warsaw, Poland;
Sean O'HearnMorton Mower Central Research Laboratory, Sinai Hospital of Baltimore, Baltimore, MD 21215;
Shawn LevyGenomics Sevices Laboratory, HudsonAlpha Institute for Biotechnology, Huntsville, AL 35806;
Prasanth PotluriCenter for Mitochondrial and Epigenomic Medicine, Children's Hospital of Philadelphia and the Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104;
Maria LvovaCenter for Mitochondrial and Epigenomic Medicine, Children's Hospital of Philadelphia and the Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104;
Antonio DavilaCenter for Mitochondrial and Epigenomic Medicine, Children's Hospital of Philadelphia and the Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104;
Chun Shi LinCenter for Mitochondrial and Epigenomic Medicine, Children's Hospital of Philadelphia and the Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104;
Juan Carlos PerinNucleic Acid/Protein Research Core Facility, Children's Hospital of Philadelphia, Philadelphia, PA 19104;
Eric F RappaportNucleic Acid/Protein Research Core Facility, Children's Hospital of Philadelphia, Philadelphia, PA 19104;
Hakon HakonarsonTrovagene, San Diego, CA 92130;
Ian A TrounceCentre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, East Melbourne, VIC 3002, Australia; and.
Vincent ProcaccioDepartment of Biochemistry and Genetics, National Center for Neurodegenerative and Mitochondrial Diseases, Centre Hospitalier Universitaire d'Angers, 49933 Angers, France.
Douglas C WallaceCenter for Mitochondrial and Epigenomic Medicine, Children's Hospital of Philadelphia and the Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104; wallaced1@email.chop.edu.
Children's Hospital of Philadelphia · USUniversity of Pennsylvania · USCentre for Eye Research Australia · AUCentre Hospitalier Universitaire d'Angers · FRGenomics (United Kingdom) · GBHudsonAlpha Institute for Biotechnology · USSinai Hospital · USUniversity of Hong Kong · HKUniversity of Warsaw · PL

Funding

MITOCHONDRIAL INBORN ERRORS OF METABOLISMR01NS021328 · NINDS · UNIVERSITY OF CALIFORNIA-IRVINE · PI WALLACE, DOUGLAS C · 1985 to 2017
$6.5M
Adaptive Physiology of mtDNA Longevity MutationsR01AG024373 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI WALLACE, DOUGLAS C · 2004 to 2008
$1.9M
Mitochondrial Diabetes & Manganic Porphyrin TreatmentR01DK073691 · NIDDK · UNIVERSITY OF CALIFORNIA-IRVINE · PI WALLACE, DOUGLAS C · 2006 to 2010
$1.5M
A Mitochondrial Etiology of AutismR01NS070298 · NINDS · UNIVERSITY OF CALIFORNIA-IRVINE · PI WALLACE, DOUGLAS C · 2009 to 2010
$1.3M
CIHRNIA NIH HHS AG24373NIA NIH HHS R01 AG024373NIDDK NIH HHS DK73691NIDDK NIH HHS R01 DK073691NINDS NIH HHS NS070298NINDS NIH HHS NS21328NINDS NIH HHS R01 NS021328NINDS NIH HHS R01 NS070298
6 · The paper itself

Abstract

Variation in the intracellular percentage of normal and mutant mitochondrial DNAs (mtDNA) (heteroplasmy) can be associated with phenotypic heterogeneity in mtDNA diseases. Individuals that inherit the common disease-causing mtDNA tRNA(Leu(UUR)) 3243A>G mutation and harbor ∼10-30% 3243G mutant mtDNAs manifest diabetes and occasionally autism; individuals with ∼50-90% mutant mtDNAs manifest encephalomyopathies; and individuals with ∼90-100% mutant mtDNAs face perinatal lethality. To determine the basis of these abrupt phenotypic changes, we generated somatic cell cybrids harboring increasing levels of the 3243G mutant and analyzed the associated cellular phenotypes and nuclear DNA (nDNA) and mtDNA transcriptional profiles by RNA sequencing. Small increases in mutant mtDNAs caused relatively modest defects in oxidative capacity but resulted in sharp transitions in cellular phenotype and gene expression. Cybrids harboring 20-30% 3243G mtDNAs had reduced mtDNA mRNA levels, rounded mitochondria, and small cell size. Cybrids with 50-90% 3243G mtDNAs manifest induction of glycolytic genes, mitochondrial elongation, increased mtDNA mRNA levels, and alterations in expression of signal transduction, epigenomic regulatory, and neurodegenerative disease-associated genes. Finally, cybrids with 100% 3243G experienced reduced mtDNA transcripts, rounded mitochondria, and concomitant changes in nuclear gene expression. Thus, striking phase changes occurred in nDNA and mtDNA gene expression in response to the modest changes of the mtDNA 3243G mutant levels. Hence, a major factor in the phenotypic variation in heteroplasmic mtDNA mutations is the limited number of states that the nucleus can acquire in response to progressive changes in mitochondrial retrograde signaling.

Indexed as

DNA, MitochondrialEpigenesis, GeneticMitochondriaPoint MutationRNA, MessengerTranscription, GeneticCell Line, TumorGenetic Diseases, InbornGlycolysisHumansRNA, Transfer, LeuSequence Analysis, RNASignal TransductionDNA, MitochondrialRNA, MessengerRNA, Transfer, Leuelectron microscopyepigeneticmitochondrial diseasemtDNA variantRNA-Seq

Identifiers

PMID25192935
PMCPMC4183335
OpenAlexW2078475387

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.